EBV vaccine

A method for vaccinating a subject, the method comprising:

• (A) contacting said subject with
• (i) a composition comprising Epstein-Barr Virus (EBV) particles, wherein said EBV particles comprise a reduced chromosome instability-inducing EBV polypeptide activity,
• (ii) a polynucleotide encoding an EBV genome, wherein said EBV genome
• a) lacks a gene encoding a functional chromosome instability-inducing EBV polypeptide and/or lacks a gene encoding a functional EBV fusogenic polypeptide, and
• b) lacks EBV terminal repeat sequences and/or lacks at least one functionally expressible gene selected from the BFLF1 gene and the BBRF1 gene,
• (iii) a vector comprising the polynucleotide of (ii),
• (iv) a host cell comprising the polynucleotide of (ii) or the vector of (iii), or
• (v) any combination of (A)(i) to (A)(iv);
• and
• (B) thereby, vaccinating said subject while avoiding induction of chromosomal aberrations by said vaccination,
• wherein said subject is a human of less than 18 years of age, is suffering from immunodeficiency, is planned to undergo immunosuppressive treatment, is planned to undergo a transplant, or is any combination thereof.